EchoGo Amyloidosis vs Us2.v2

When choosing between Ultromics’ EchoGo Amyloidosis and Us2.v2, a key practical difference lies in their scope and focus. EchoGo Amyloidosis is a specialized screening tool for cardiac amyloidosis, analyzing echocardiogram video clips to identify patients at risk with high accuracy. It provides a diagnostic output of ‘suggestive’ or ‘not suggestive’ of cardiac amyloidosis and integrates with existing clinical workflows. Its pricing structure includes specific codes for inpatient and outpatient analyses, potentially simplifying billing for this targeted use case.

In contrast, Us2.v2 offers a broader, automated echocardiogram interpretation solution, generating a complete structured echo report with measurements, disease detection, and clinical findings for various conditions, including cardiac amyloidosis, aortic stenosis, and heart failure. It aims to reduce reporting time and increase scan throughput by automating frame selection and annotation. Us2.v2 also provides flexibility with both cloud and on-premise deployment options.

Therefore, a physician primarily focused on enhancing early detection of cardiac amyloidosis within their existing workflow might favor EchoGo Amyloidosis due to its specialized accuracy and clear billing structure for this specific condition. Conversely, a physician seeking to streamline and automate the interpretation and reporting of a wide range of echocardiogram findings, improving overall efficiency and throughput, would likely find Us2.v2 more suitable. The choice hinges on whether the priority is a highly targeted screening tool or a comprehensive automation solution for echocardiography analysis.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist